- The company will also present at the Industry Symposium on “Gene Expression for Risk Assessment in Primary Melanoma — The Merlin Assay in Clinical Practice”
- SkylineDx is exhibiting at Booth #24
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), September 9th, 2025— SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, and inflammatory and infectious diseases, will launch its new European patient access program, Merlin for Me®, at the ADO Congress 2025. During an industry symposium, SkylineDx will also present how Merlin Assay’s gene expression (CP-GEP) analyses can precisely assess the risk of primary melanoma recurrence, based on recent scientific studies. ADO Congress 2025 is taking place September 10-13, 2025, in Essen, Germany, at Messehaus Ost.
Merlin for Me will have an initial rollout in Germany, aiming to help early-stage melanoma patients access the Merlin test with reduced administrative and financial burden by navigating insurance, accessing support services, and receiving targeted education tools. The program is an extension of Merlin’s value in providing access to genomic testing for patients with melanoma and their clinicians. Beyond Germany, SkylineDx plans to implement the program in additional European regions in 2026.
“In clinical settings, we’ve proven that the Merlin Assay is an effective tool for clinicians to accurately determine whether patients with melanoma have a high risk for metastasis, and therefore must undergo Sentinel Lymph Node Biopsy,” said SkylineDx CEO Dharminder Chahal. “Sentinel Lymph Node Biopsy is an invasive procedure that can have complications, so if we can help clinicians eliminate unnecessary surgeries, patients can receive better care. Patients are the exact reason why we developed the Merlin for Me program – we want to provide access to the Merlin Assay regardless of economic status.”
Industry Symposium Details:
Presentation Title: Gene Expression for Risk Assessment in Primary Melanoma — The Merlin Assay in Clinical Practice
Date/Time: Thursday, September 11, 2025 at 4:45 – 5:45 p.m. CET
Location: Room C
Presenters: Dr. Teresa Amaral, University of Tübingen, and Prof. Dr. Med. Thomas Eigentler, Charité – Universitätsmedizin Berlin
Program Details:
• 4:45 – 5:15 p.m. CET: Scientific Basis and Clinical Significance — Dr. Teresa Amaral
• 5:15 – 5:45 p.m. CET: Case-Based Application of the Merlin Assay in Clinical Practice — Prof. Thomas Eigentler, Dr Teresa Amaral and Dr. Georg Frey.
SkylineDx is available to discuss the Merlin Assay, recent clinical findings and the Merlin for Me program at Booth #24.
About the Merlin Assay (CP-GEP)
CP-GEP is a non-invasive prediction model for cutaneous melanoma patients and is the only commercially available GEP test that combines clinicopathologic (CP) variables with gene expression profiling (GEP) into a single integrated algorithm. This CP-GEP model is also the only GEP test that provides a binary stratification of all patients based on being High or Low Risk for metastasis and thereby assigns them to the appropriate surgical action categories as listed in evidence-based cancer treatment, prevention, and screening guidelines. The advanced CP-GEP model was developed by Mayo Clinic and SkylineDx and is the latest commercially launched GEP test, which has been clinically validated in multiple studies on a global basis. The test has been launched in the United States and Europe as Merlin. SkylineDx collaborates with diagnostic service providers globally to bring this test to market and increase patient access. More information (including references) may be obtained at www.falconprogram.com and www.merlinmelanomatest.com.
About SkylineDx
SkylineDx is a biotechnology company focused on research and development of molecular diagnostics in oncology, and inflammatory and infectious diseases. SkylineDx uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, assisting healthcare professionals in accurately determining the type or status of disease or predicting a patient’s response to treatment. Based on test results, healthcare professionals can tailor the treatment approach to the individual patient. SkylineDx is headquartered in Rotterdam, the Netherlands, complemented by a US base of operations and a CAP/CLIA certified laboratory in San Diego California, USA. To learn more about SkylineDx, please visit www.skylinedx.com.
